Mobility Opportunities Via Education/Experience (MOVE): Healthcare Impact Assessment

计划入组 130 人 · 首次发布于 2023 年 5 月 17 日

Night Owl Metabolism

计划入组 70 人 · 首次发布于 2024 年 7 月 18 日

Diagnostic Accuracy Study for OWL-EVO1 as a Lung Cancer EVOC® Probe (Evolution Phase 2)

计划入组 187 人 · 首次发布于 2024 年 1 月 5 日

OWL-1023

OWL-4130

OWL-1975

BLUE CARIBE, INC.

United States

MainStay MacKay DefinedTerm Municipal Opportunities Fund

United States

NAOS Ex-50 Opportunities Company Ltd

Ovid Therapeutics Secures $175M PIPE Financing to Advance CNS Drug Pipeline Through 2028

Novo Holdings Leads $200M Series A Investment in Windward Bio for Advanced Respiratory Treatments

Aviceda Therapeutics Secures $207.5 Million to Advance Geographic Atrophy Treatment